Wave Life Sciences (WVE) Earnings Date & Reports

Wave Life Sciences posted a Q4 net loss of $53.2 million, or $(0.30) per share, wider than the prior year's net income of $29.3 million ($0.18 basic per share), and missing consensus EPS estimates of about $(0.27). Full-year net loss reached $204.4 million ($(1.21) per share), up from $97.0 million ($(0.70) per share).

Revenue totaled $17.2 million, surpassing some estimates near $15.7 million but plunging 79% from $83.7 million, reflecting reduced collaboration recognition; FY revenue was $42.7 million versus $108.3 million. Expenses rose with R&D at $52.8 million (up from $44.6 million) and G&A at $20.9 million (up from $16.1 million), fueling pipeline advancement.

Cash and equivalents stood at $602.1 million, doubled from $302.1 million, bolstered by equity financing and GSK payments. No new formal guidance was issued, but management affirmed runway into Q3 2028 and upcoming catalysts like INLIGHT Q1 data.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Shares surged 5.6% to $15.36 on February 26, 2026, post-earnings, adding ~$146 million to market cap, driven by pipeline enthusiasm despite the EPS miss. The next day, shares dipped to $13.93, reflecting volatility typical in biotech after mixed financials overshadowed by clinical promise. Sentiment remains cautiously optimistic, buoyed by strong cash and obesity/AATD data, though revenue decline tempers expectations.

Forward Outlook and Key Factors to Monitor

Investors should track Q1 2026 clinical readouts, including six-month data from INLIGHT's 240 mg cohort and three-month from 400 mg for WVE-007, Wave's obesity candidate showing GLP-1-like fat loss with muscle preservation. Phase 2a multidose starts H1 2026, alongside add-on/post-incretin trials.

For WVE-006 in AATD, monitor 400 mg multidose data (Q1) and regulatory feedback on accelerated approval (mid-2026). RestorAATion-2's 600 mg data follows in 2026. WVE-N531 NDA for DMD and WVE-008 CTA (liver disease) target 2026 filings.

Financially, consensus eyes Q1 EPS ~$(0.31) and revenue ~$7.9 million. GSK collaboration advances (fourth program selected) could trigger milestones. Cash burn amid R&D ramp-up warrants attention, balanced by $602 million runway.

Broader dynamics include obesity market competition and RNA tech validation. Upcoming data could catalyze sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations